RD Biomed is a Yorkshire-based SME looking to bring to market Peptest, a novel diagnostic test for reflux disease. Peptest has been widely validated in the laboratory, and clinical studies but how to best access the NHS and market the product in primary and secondary care was a major barrier to progress and a daunting prospect for an SME such as ours.
As Peptest can be used in a number of different market sectors (primary and secondary care), it was important that a targeted, coherent and well referenced approach was adopted that enabled RD Biomed to clearly demonstrate the clinical and economic benefits of Peptest to key stakeholders within the NHS.
M.A.R.S Ltd quickly identified a number of strategies for approaching the different sectors of the NHS and with their expertise we were able to build strong economic models and business cases that were invaluable in our discussions with clinical commissioning groups, AHSNs and hospital trusts alike. The value propositions that we were able to present to potential purchasers and clinical teams represented a step change in our engagement with the NHS and has enabled us to develop working relationships in primary and secondary care and has resulted in the use of our product in these settings. MAARS actively engaged in every stage of the project from producing models to meeting customers to reviewing our own performance in meetings.
Throughout the process M.A.R.S Ltd demonstrated a deep understanding of the various NHS channels and the types of information that made a real difference to decision makers, they were pro-active, extremely professional and a pleasure to work with throughout the project.
I am hapy to recommend M.A.R.S Ltd
Harvey Dettmar (Director)
RDBiomed Limited
